Long-Term Survival for 8 Years of Peritoneal Recurrence of a Gastric Cancer Treated with S-1/docetaxel Combination Chemotherapy-Reference-Cited by-同舟云学术

Long-Term Survival for 8 Years of Peritoneal Recurrence of a Gastric Cancer Treated with S-1/docetaxel Combination Chemotherapy

Published:2018-09-01 Issue:9 Volume:51 Page:566-572
ISSN:0386-9768
Container-title:The Japanese Journal of Gastroenterological Surgery
language:en
Short-container-title:Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi

Author:

Sekino Yasushi¹,Koyano Yasuhiro¹,Shimodaira Yusuke¹,Takahashi Yusuke¹,Okada Masao¹,Hayashibara Kaori¹,Sakon Masahiro¹,Takata Manabu¹,Seki Hitoshi¹,Munakata Yasuhiro¹

Affiliation:

1. Department of Surgery, Nagano Municipal Hospital

Publisher

The Japanese Journal of Gastroenterological Surgery

Subject

Gastroenterology,Surgery

Link

https://www.jstage.jst.go.jp/article/jjgs/51/9/51_2017.0158/_pdf

Reference11 articles.

1. 1) Kakeji Y, Maehara Y, Tomoda M, Kabashima A, Ohmori M, Oda S, et al. Long-term survival of patients with stage IV gastric carcinoma. Cancer. 1998 Jun;82(12):2307–2311.

2. 2) Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imamoto H, et al. Phase III study of intraperitoneal paclitaxel plus s-1/paclitaxel compared with s-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 34, 2016 (suppl; abstr 4014)

3. 3) Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomized controlled trial. Lancet Oncol. 2016 Mar;17(3):309–318.

4. 6) Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 2006 Jun;12(11):3402–3407.

5. 7) Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, et al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol. 2006 Mar;12(9):1412–1415.